Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022777 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CES2CES1EPHX1HIF1A | |
| SCHEMBL3036858 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CES2CES1EPHX1HIF1A | |
| SCHEMBL59917 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CES2CES1EPHX1HIF1A | |
| SCHEMBL1920807 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CES2CES1EPHX1HIF1A | |
| SCHEMBL95619 | 1.00 | — | — | |
| SCHEMBL3027678 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CES2CES1EPHX1HIF1A | |
| SCHEMBL1920210 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CES2CES1EPHX1HIF1A | |
| SCHEMBL3034311 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CES2CES1EPHX1HIF1A | |
| SCHEMBL26096 | 1.00 | — | — | |
| SCHEMBL1218164 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CES2CES1EPHX1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162937-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS LTD. (FI) | 2014-06-12 | — | — | US | claimed |
| US-8680234-B2 | Polymyxin derivatives and uses thereof | NORTHERN ANTIBIOTICS OY (FI) | 2014-03-25 | — | — | US | claimed |
| US-8329645-B2 | Polymyxin derivatives and uses thereof | NORTHERN ANTIBIOTICS LTD. (FI) | 2012-12-11 | — | — | US | claimed |
| US-20100292136-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS OY (FI) | 2010-11-18 | — | — | US | claimed |
| US-20090215677-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS LTD. (FI) | 2009-08-27 | — | — | US | claimed |
| EP-4373836-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2024-05-29 | — | — | EP | disclosed |
| CN-117693517-A | Novel compounds and compositions for targeted treatment of renal cancer | 上海盟科药业股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117642419-A | Compounds and compositions for targeted treatment of kidney disease | 上海盟科药业股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023116734-A1 | FUSED PYRROLIDINE COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY VIRAL INFECTIONS | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-06-29 | — | — | WO | disclosed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2023001224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001223-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-01-26 | — | — | WO | disclosed |
| EP-0434080-A1 | Derivatives of N-hals-substituted amic acid hydrazides | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1991-06-26 | — | — | EP | disclosed |
| EP-0434079-A1 | N,N'-hydrocarbylenebis(N-hals-substituted amic acid hydrazides) and their derivatives | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1991-06-26 | — | — | EP | disclosed |
| EP-0377633-A4 | PEROXIDE FREE RADICAL INITIATORS CONTAINING HINDERED AMINE LIGHT STABILIZER GROUPS | — | 1991-01-30 | — | — | EP | disclosed |
| EP-0377633-A1 | PEROXIDE FREE RADICAL INITIATORS CONTAINING HINDERED AMINE LIGHT STABILIZER GROUPS. | PENNWALT CORP (US) | 1990-07-18 | — | — | EP | disclosed |
| US-4925903-A | PEROXIDE CONTAINING HINDERED AMINE ALSO FUNCTIONS AS INITIATOR | PENNWALT CORPORATION (US) | 1990-05-15 | — | — | US | disclosed |
| US-4885347-A | UNSATURATED POLYESTER | PENNWALT CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| US-4822883-A | 2,2,6,6-TETRA SUBSTITUTED PIPERIDIN-4-YL PEROXY DERIVATIVES BECOMING CHEMICALLY BONDED TO ADDITION POLYMER | PENNWALT CORPORATION (US) | 1989-04-18 | — | — | US | disclosed |
| WO-1989001474-A1 | PEROXIDE FREE RADICAL INITIATORS CONTAINING HINDERED AMINE LIGHT STABILIZER GROUPS | PENNWALT CORPORATION (US) | 1989-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215677-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | C5, C9, C3AR1 | ALDH1A1 4876/4885CES2 4709/4885CES1 3391/4885 |
| US-20140162937-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | SLC11A2, TLR2, TLR5 | ALDH1A1 4808/4885CES2 4455/4885CES1 3527/4885 |
| US-20100292136-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | C5, C9, C3AR1 | ALDH1A1 4876/4885CES2 4709/4885CES1 3391/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | ALDH1A1 1860/4885CES2 4827/4885CES1 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.